In light of the above, there are no clinical studies that clearly indicate a negative effect of the use of GLP1-RAs in diabetic patients already suffering from colon cancer, in those under chemotherapy treatment, or those with a newly developed colon cancer. The gene discussed is GLP1R; the disease is colonic neoplasm.